Outcomes of ICU patients treated with intravenous immunoglobulin for sepsis or autoimmune diseases

Tocut, Milena; Kolitz, Tamara; Shovman, Ora; Haviv, Yael; Boaz, Mona; Laviel, Shira; Debi, Stav; Nama, Mona; Akria, Amir; Shoenfeld, Yehuda; Soroksky, Arie; Zandman‐Goddard, Gisele

doi:10.1016/j.autrev.2022.103205

Cited by 6 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the 2020 international guidelines of the Save Sepsis Campaign, it is stated that it is not recommended that children with septic shock or sepsisassociated organ dysfunction to be routinely treated with IV gammaglobulin, but certain children may benefit from it (24). Some studies have also reported conflicting results (25)(26)(27). At present, there are no high-quality studies on immunoglobulin treatment of sepsis in children, and adequate clinical trials are still needed to determine the efficacy of immunoglobulin and to provide a more reliable basis for clinical treatment.…”

Section: At the Bedsidementioning

confidence: 99%

Epidemiology and Clinical Characteristics of Pediatric Sepsis in PICUs in Southwest China: A Prospective Multicenter Study*

Liu,

Yu,

Xiao

et al. 2024

Pediatric Critical Care Medicine

View full text Add to dashboard Cite

Objectives: To describe the epidemiological characteristics of pediatric sepsis in Southwest China PICUs. Design: A prospective, multicenter, and observational study. Setting: Twelve PICUs in Southwest China. Patients: The patients admitted to the PICU from April 1, 2022, to March 31, 2023. The age ranged from 28 days to 18 years. All patients met the criteria of severe sepsis or septic shock. Interventions: None. Measurements and Main Results: Of the 31 PICUs invited to participate, 12 PICUs (capacity of 292 beds) enrolled patients in the study. During the study period, 11,238 children were admitted to the participating PICUs, 367 (3.3%) of whom met the diagnosis of severe sepsis or septic shock. The most prevalent sites of infection were the respiratory system (55%) and the digestive system (15%). The primary treatments administered to these patients included antibiotics (100%), albumin (61.3%), invasive mechanical ventilation (58.7%), glucocorticoids (55.6%), blood products (51%), gammaglobulin (51%), and vasoactive medications (46.6%). Sepsis-related mortality in the PICU was 11.2% (41/367). Nearly half of the sepsis deaths occurred within the first 3 days of PICU admission (22/41, 53.7%). The mortality rate of septic shock (32/167, 19.2%) was significantly higher than that of severe sepsis (9/200, 4.5%; p < 0.001). The outcomes of a multivariate logistic regression analysis suggested that a higher pediatric Sequential Organ Failure Assessment score, and the use of invasive mechanical ventilation and vasoactive medications were independently associated with PICU mortality in children with sepsis. Conclusions: This report updates the epidemiological data of pediatric sepsis in PICUs in Southwest China. Sepsis is still a life-threatening disease in children.

show abstract

Section: At the Bedsidementioning

confidence: 99%

Epidemiology and Clinical Characteristics of Pediatric Sepsis in PICUs in Southwest China: A Prospective Multicenter Study*

Liu,

Yu,

Xiao

et al. 2024

Pediatric Critical Care Medicine

View full text Add to dashboard Cite

show abstract

“…It is composed of several types of antibodies, such as IgG, IgM, and IgA, which are extracted from blood plasma. 16 A meta-analysis reported that about 70% of septic patients present with low plasma IG on the day of sepsis onset. 17 Given this finding, IVIG was used in clinical trials to evaluate the therapeutic potential in sepsis patients.…”

Section: Current Immunotherapy For Sepsis-induced Immunosuppressionmentioning

confidence: 99%

Clinical practice of sepsis-induced immunosuppression: Current immunotherapy and future options

Pei,

Gu,

Miao

et al. 2024

Chinese Journal of Traumatology

View full text Add to dashboard Cite

“…A single-center retrospective study of 239 patients with sepsis showed that IVIG significantly improved the prognosis of patients with low IgG levels and reduced mortality. A retrospective multicenter study of 850 patients with severe COVID-19 showed that IVIG did not significantly improve the 28-day survival rate of patients, and might have induced adverse thrombosis and allergic reactions [ 58 , 59 ].…”

Section: Antibody Drugsmentioning

confidence: 99%

Research Progress of Macromolecules in the Prevention and Treatment of Sepsis

Su,

Wu,

Zhou

et al. 2023

IJMS

View full text Add to dashboard Cite

Sepsis is associated with high rates of mortality in the intensive care unit and accompanied by systemic inflammatory reactions, secondary infections, and multiple organ failure. Biological macromolecules are drugs produced using modern biotechnology to prevent or treat diseases. Indeed, antithrombin, antimicrobial peptides, interleukins, antibodies, nucleic acids, and lentinan have been used to prevent and treat sepsis. In vitro, biological macromolecules can significantly ameliorate the inflammatory response, apoptosis, and multiple organ failure caused by sepsis. Several biological macromolecules have entered clinical trials. This review summarizes the sources, efficacy, mechanism of action, and research progress of macromolecular drugs used in the prevention and treatment of sepsis.

show abstract

Outcomes of ICU patients treated with intravenous immunoglobulin for sepsis or autoimmune diseases

Cited by 6 publications

References 39 publications

Epidemiology and Clinical Characteristics of Pediatric Sepsis in PICUs in Southwest China: A Prospective Multicenter Study*

Epidemiology and Clinical Characteristics of Pediatric Sepsis in PICUs in Southwest China: A Prospective Multicenter Study*

Clinical practice of sepsis-induced immunosuppression: Current immunotherapy and future options

Research Progress of Macromolecules in the Prevention and Treatment of Sepsis

Contact Info

Product

Resources

About